Introductory paper: High-dose influenza vaccine.

Authors :: Diaco M
Chang LJ
Seet B
Robertson CA
Chit A
Mercer M
Greenberg DP
Hollingsworth R
Samson SI
Source :: Vaccine [Vaccine] 2021 Mar 15; Vol. 39 Suppl 1, pp. A1-A5. Date of Electronic Publication: 2021 Feb 03.
Publication Year :: 2021
Abstract: Seasonal influenza has a significant impact on global public health each year, especially in older adults 65 years of age and above. This paper presents the evolution of high-dose influenza vaccine and the quantity as well as quality of evidence on this vaccine. Its introduces other peer-reviewed manuscripts included in this supplement covering the benefits high-dose influenza vaccine over ten consecutive influenza seasons. The development of the high-dose influenza vaccine represents an important step in the evolution of influenza vaccines, offering an advancement in prevention of influenza and a step in encouraging healthy aging in older adults. A video summary of the article can be accessed via the Supplementary data link at the end of this article.<br />Competing Interests: Declaration of Competing Interest MD, LJC, BS, CR, AC, MM, DPG, RH, and SIS are employees of Sanofi Pasteur.<br /> (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)